How Dual and Triple Agonists Like Tirzepatide Work Inside Pancreatic Cells
Dual and triple receptor agonists that target GLP-1, GIP, and glucagon receptors simultaneously show strong clinical results for diabetes, but scientists still don't fully understand how activating multiple receptors at once changes cell signaling.
Quick Facts
What This Study Found
Clinical studies of dual GLP-1/GIP receptor agonists (unimolecular dual-receptor agonists or UDRAs) have demonstrated favorable results both as standalone treatments and in combination with other diabetes drugs. The additive insulin-boosting effects of dual GLP-1 and GIP receptor activation were expected based on what each hormone does individually.
However, the additional benefits from adding glucagon receptor (GCGR) activation in triple agonists were largely unexpected, since glucagon normally raises blood sugar. Whether simultaneous stimulation of these three receptor pathways creates synergistic or antagonistic interactions at the cellular level remains unknown and requires further investigation.
Key Numbers
How They Did This
This was a scoping review examining the published literature on the cellular mechanisms of action of dual- and triple-receptor agonist peptides in pancreatic islet cells. The authors analyzed studies covering the signaling pathways activated by GLP-1, GIP, and glucagon receptors individually and in combination, drawing on both preclinical mechanistic studies and clinical efficacy trials.
Why This Research Matters
Drugs like tirzepatide (a dual GLP-1/GIP agonist) and retatrutide (a triple agonist) represent a major shift in diabetes and obesity treatment. Understanding exactly how these drugs work at the cellular level is essential for predicting long-term safety, optimizing dosing, and designing even better multi-agonist peptides. The finding that glucagon receptor activation provides unexpected benefits challenges conventional thinking about diabetes treatment.
The Bigger Picture
Multi-agonist peptides are the hottest area in metabolic drug development. Tirzepatide's dual agonism produced unprecedented weight loss and blood sugar control, and triple agonists like retatrutide are pushing results even further. This review highlights an important gap: these drugs are already in patients' hands, but the scientific understanding of how simultaneous multi-receptor activation works at the cellular level is still catching up to the clinical results.
What This Study Doesn't Tell Us
As a scoping review, this paper maps the current state of knowledge rather than providing new experimental data. The authors acknowledge that the signaling pathway interactions from simultaneous dual and triple receptor stimulation require much deeper investigation. Most mechanistic understanding comes from studying each receptor pathway individually, which may not capture the complexity of simultaneous activation.
Questions This Raises
- ?Do the three receptor pathways (GLP-1, GIP, glucagon) interact synergistically inside cells, or do some effects cancel each other out?
- ?Why does glucagon receptor activation — which normally raises blood sugar — provide metabolic benefits when combined with GLP-1 and GIP agonism?
- ?Could understanding the combined signaling pathways reveal new safety concerns not apparent from studying each receptor alone?
Trust & Context
- Key Stat:
- 3 receptors, 1 molecule Triple agonists simultaneously activate GLP-1, GIP, and glucagon receptors — and the glucagon benefit was unexpected, since glucagon normally raises blood sugar.
- Evidence Grade:
- This is a scoping review that synthesizes existing mechanistic and clinical literature rather than presenting original data. While it references clinical trial results, its primary contribution is conceptual — mapping knowledge gaps in multi-receptor agonist signaling.
- Study Age:
- Published in 2023, this review covers the state of multi-agonist peptide research through 2023. The field is evolving rapidly with ongoing phase III trials for retatrutide and other triple agonists, so new mechanistic insights may have emerged since publication.
- Original Title:
- Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.
- Published In:
- American journal of physiology. Endocrinology and metabolism, 325(5), E595-E609 (2023)
- Authors:
- Folli, Franco, Finzi, Giovanna, Manfrini, Roberto, Galli, Alessandra, Casiraghi, Francesca, Centofanti, Lucia, Berra, Cesare, Fiorina, Paolo, Davalli, Alberto, La Rosa, Stefano, Perego, Carla, Higgins, Paul B
- Database ID:
- RPEP-06880
Evidence Hierarchy
Frequently Asked Questions
What's the difference between a dual agonist and a triple agonist for diabetes?
A dual agonist like tirzepatide activates two hormone receptors at once (GLP-1 and GIP), both of which boost insulin release and reduce appetite. A triple agonist adds glucagon receptor activation on top of that. Counterintuitively, activating the glucagon receptor — which normally raises blood sugar — appears to provide additional metabolic benefits, possibly by increasing energy expenditure and fat burning.
If these drugs work so well clinically, why does it matter that scientists don't fully understand the mechanism?
Understanding how a drug works at the cellular level is critical for predicting long-term safety, identifying who will respond best, and designing improved versions. When multiple receptor pathways are activated simultaneously, unexpected interactions could emerge over years of use that wouldn't be apparent in short-term trials.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06880APA
Folli, Franco; Finzi, Giovanna; Manfrini, Roberto; Galli, Alessandra; Casiraghi, Francesca; Centofanti, Lucia; Berra, Cesare; Fiorina, Paolo; Davalli, Alberto; La Rosa, Stefano; Perego, Carla; Higgins, Paul B. (2023). Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.. American journal of physiology. Endocrinology and metabolism, 325(5), E595-E609. https://doi.org/10.1152/ajpendo.00236.2023
MLA
Folli, Franco, et al. "Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets.." American journal of physiology. Endocrinology and metabolism, 2023. https://doi.org/10.1152/ajpendo.00236.2023
RethinkPeptides
RethinkPeptides Research Database. "Mechanisms of action of incretin receptor based dual- and tr..." RPEP-06880. Retrieved from https://rethinkpeptides.com/research/folli-2023-mechanisms-of-action-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.